The menopause

被引:406
作者
Greendale, GA
Lee, NP
Arriola, ER
机构
[1] Univ Calif Los Angeles, Sch Med, Div Geriatr, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Ctr Hlth Sci, Dept Pharmaceut Serv, Los Angeles, CA 90095 USA
关键词
D O I
10.1016/S0140-6736(98)05352-5
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Menopause is diagnosed after 12 months of amenorrhoea resulting from the permanent cessation of ovarian function. The mean age at menopause is 51 years. The perimenopause, a time of changing ovarian function, precedes the final menses by several years. The physiology and clinical manifestations of this transition to menopause are not well understood; however, some symptoms, such as hot flashes, certainty begin in the perimenopause. Causal associations between menopause and several symptoms and diseases are proposed. The evidence for these associations varies and is reviewed. Hormone replacement therapy can be directed-at symptom relief or at prevention or treatment of chronic diseases. Doses and routes of hormone replacement therapy vary by indication. Complications of hormone replacment therapy depend on the regimen used. Knowing the expected vaginal bleeding pattern for each hormone replacement therapy regimen is important, since unexpected bleeding may signal endometrial hyperplasia. Postmenopausal hormone therapy is a complex intervention that produces positive and negative specific health effects. Overall, based on observational studies, postmenopausal women who use hormones have a 30-50% lower all-cause mortality rate than those who do not use hormones. It is important to recognise that the value that individual women place on various health outcomes associated with hormone replacement therapy may differ. Thus, the decision to use hormone replacement therapy should be made jointly by each woman and her health-care provider, after careful consideration of possible benefits, risks, and her personal preferences.
引用
收藏
页码:571 / 580
页数:10
相关论文
共 122 条
[1]
*ACOG COMM OP, 1993, J GYNECOL OBSTET, V43, P89
[2]
*AM COLL OBST GYN, 1992, ACOG TECHN B, V166, P166
[3]
AMY JJ, 1993, INT J FERTIL, V38, P5
[4]
ARCHER DF, 1994, OBSTET GYNECOL, V83, P686
[5]
Avis Nancy E., 1994, Annals of Epidemiology, V4, P214
[6]
A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy [J].
Ayton, RA ;
Darling, GM ;
Murkies, AL ;
Farrell, EA ;
Weisberg, E ;
Selinus, I ;
Fraser, IS .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1996, 103 (04) :351-358
[8]
LOW-DOSE PROGESTERONE THERAPY IN ESTROGENIZED POSTMENOPAUSAL WOMEN - EFFECTS ON PLASMA-LIPIDS, LIPOPROTEINS AND LIVER-FUNCTION PARAMETERS [J].
BOLAJI, II ;
GRIMES, H ;
MORTIMER, G ;
TALLON, DF ;
FOTTRELL, PF ;
ODWYER, EM .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1993, 48 (01) :61-68
[9]
Ultrasound in gynecology: Endometrium [J].
Bourne, T ;
Hamberger, L ;
Hahlin, M ;
Granberg, S .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1997, 56 (02) :115-127
[10]
Hormone replacement therapy and risk for breast cancer [J].
Brinton, LA .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1997, 26 (02) :361-+